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ABSTRACT
Objectives: To synthesize methodologically comparable evidence from the published literature regarding the outcomes of tiered
formularies and therapeutic reference pricing of prescription drugs.
Methods: We searched the following electronic databases: ABI/Inform, CINAHL, Clinical Evidence, Digital Dissertations &
Theses, Evidence­Based Medicine Reviews (which incorporates ACP Journal Club, Cochrane Central Register of Controlled
Trials, Cochrane Database of Systematic Reviews, Cochrane Methodology Register, Database of Abstracts of Reviews of
Effectiveness, Health Technology Assessments and NHS Economic Evaluation Database), EconLit, EMBASE, International
Pharmaceutical Abstracts, MEDLINE, PAIS International and PAIS Archive, and the Web of Science. We also searched the
reference lists of relevant articles and several grey literature sources. We sought English­language studies published from 1986 to
2007 that examined the effects of either therapeutic reference pricing or tiered formularies, reported on outcomes relevant to
patient care and cost­effectiveness, and employed quantitative study designs that included concurrent or historical comparison
groups. We abstracted and assessed potentially appropriate articles using a modified version of the data abstraction form
developed by the Cochrane Effective Practice and Organisation of Care Group.
Results: From an initial list of 2964 citations, 12 citations (representing 11 studies) were deemed eligible for inclusion in our
review: 3 studies (reported in 4 articles) of reference pricing and 8 studies of tiered formularies. The introduction of reference
pricing was associated with reduced plan spending, switching to preferred medicines, reduced overall drug utilization and short­
term increases in the use of physician services. Reference pricing was not associated with adverse health impacts. The
introduction of tiered formularies was associated with reduced plan expenditures, greater patient costs and increased rates of
non­compliance with prescribed drug therapy. From the data available, we were unable to examine the hypothesis that tiered
formulary policies result in greater use of physician services and potentially worse health outcomes.
Conclusion: The available evidence does not clearly differentiate between reference pricing and tiered formularies in terms of
policy outcomes. Reference pricing appears to have a slight evidentiary advantage, given that patients’ health outcomes under
tiered formularies have not been well studied and that tiered formularies are associated with increased rates of medicine
discontinuation.
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M
OST COMMUNITY­BASED SPENDING ON
prescription drugs in Canada is financed
through provincial (40%) and private (35%)
drug plans.
1 From 1997 to 2007, spending under
provincial drug plans grew from $3.1 billion to $9.2
billion, and spending under private plans grew from
$2.8 billion to $7.8 billion. Under such financial
pressures, it is possible that reference pricing and tiered
formularies will be adopted more and more by public
and private insurers in Canada. Because these coverage
policies are similar in intent but slightly different in
structure, we sought to review and compare evidence
concerning their effects. Although the authors of several
reviews and commentaries have looked at tiered
formularies and reference pricing policies,
2­5 none thus
far has conducted a systematic comparison of evidence
regarding these 2 formulary interventions.
Under reference pricing policies, a drug plan
generally covers low­cost options within specified drug
categories and requires patients to pay any price
differences if higher­cost products are prescribed.
Categories may include only chemically equivalent
drugs (generic reference pricing), or they may include
chemically distinct products with comparable
therapeutic effects (therapeutic reference pricing).
Public and private insurers in Canada and abroad use
generic reference pricing extensively. The province of
British Columbia and several countries outside Canada
have applied therapeutic reference pricing.
6,7
Under a tiered formulary, patients generally face
incrementally higher copayments for different
treatment options: a relatively low copayment applies to
“preferred” drugs within a class (e.g., $5 for generics), a
higher copayment to second­tier products within a class
(e.g., $10 for “preferred brands” for which the insurer
has negotiated a rebate) and an even higher copayment
to other drugs on the formulary (e.g., $25 for other
brands within a drug class). Tiered formularies are used
most extensively in the United States. As of 2007, 91%
of US workers with employer­sponsored drug coverage
faced at least 2 cost­sharing tiers for prescription drugs,
and 75% faced at least 3 tiers.
8
As reference pricing and tiered formularies are
already commonly used to decrease drug plan
expenditures, it is important to understand their
implications for drug costs, use of medicines and
patients’ health outcomes. Our objective in this study
was to synthesize and contrast methodologically
comparable evidence from the published literature
regarding the outcomes of both reference pricing and
tiered formulary policies.
Methods
Searching. We searched for English­language studies
published from 1986 to 2007 that examined drug plan
enrollees affected by the introduction of either
therapeutic reference pricing or tiered formularies,
reported on outcomes relevant to patient care and cost
effectiveness, and employed quantitative study designs
that included concurrent or historical comparison
groups. The starting date for the search was chosen to
predate what were believed to be the first introductions of
reference pricing policies, in 1989. Because those
formulary interventions came into use in the late 1980s, a
20­year window beginning shortly beforehand was
thought to be sufficient to capture the relevant literature.
We searched the following electronic databases:
ABI/Inform, CINAHL, Clinical Evidence, Digital
Dissertations & Theses, Evidence­Based Medicine
Reviews (which incorporates ACP Journal Club,
Cochrane Central Register of Controlled Trials,
Cochrane Database of Systematic Reviews, Cochrane
Methodology Register, Database of Abstracts of
Reviews of Effectiveness, Health Technology
Assessments and NHS Economic Evaluation Database),
EconLit, EMBASE, International Pharmaceutical
Abstracts, MEDLINE, PAIS International and PAIS
Archive, and the Web of Science. We also performed
web­based and open repository searches for grey
literature, traced citations to and from relevant articles,
hand­searched core journals from which several
citations had been found electronically and searched
our personal libraries for additional articles. We
searched databases using subject headings and key
words clustered around the concepts of prescription
drugs, the interventions of interest (using various
synonyms for copayments, tiers, and reference pricing)
and, where possible, study methodologies; see Online
Appendix 1 ( http://openmedicine.ca/article/view/
270/254) for search details.
Study selection. Articles were screened without
blinding, through a sequence of title (by DG), abstract
(by DG and SM), and full­text review and data
abstraction (by SM and GH, plus EK and JL to reconcile
discrepancies). As an aid in selecting the studies, we
used a modified version of the data abstraction form
developed by the Cochrane Effective Practice and
Organisation of Care Group.
9 We chose our inclusion
criteria to select quantitative studies that analyzed the
impact of tiered formularies or reference pricing usingResearch Morgan et al
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patient­level data in an acceptable research design. The
following designs were deemed acceptable: randomized
controlled policy trials; before­and­after, or pre/post,
studies with nonrandomized comparison groups;
interrupted time series analyses with or without
comparison groups, and pre/post studies without a
comparison group. We excluded analyses that were
based on post­only or cross­sectional designs, analyses
that used aggregated drug utilization and/or cost data,
and analyses pertaining to policies in developing
countries. We did not perform inter­rater reliability
assessments but relied on a third reviewer to resolve
discrepancies.
Data abstraction. Full­text reviewers (SM and GH)
independently abstracted data from the studies. They
first abstracted the setting in which the study had been
conducted, including the study population and
geographic setting. They then described the
intervention of interest, including an indication of
whether the intervention involved introduction of a
tiered formulary or reference pricing, the date of
introduction and the policy prior to the introduction.
The reviewers then outlined the specific outcomes that
each study examined (e.g., drug use for acute
conditions, drug expenditures, physician visits), as well
as the study design, the analytic methods and the totalResearch Morgan et al
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observation period for the study. Finally, the reviewers
independently abstracted the key findings from each
article for each outcome of interest. These abstractions
were then entered into a table, examined and translated
into narrative abstracts.
Results
We identified a total of 2964 potentially relevant
citations (Figure 1). By reviewing the citation titles, we
eliminated 2491 citations (primarily drug­specific
clinical studies). Review of the remaining abstracts
eliminated all but 86 articles. An additional 13 articles
were identified through citation tracing, of which 1
article was found to be unavailable because it was under
peer review. After full­text screening, 12 articles
representing 11 studies were deemed eligible for
inclusion in our review.
Four of the included papers, representing 3 studies,
assessed the impact of reference pricing. All of these
studies examined the implementation of reference
pricing during the mid­1990s under BC’s PharmaCare
program for senior citizens.
10­13 The other 8 studies
assessed the impact of changes in tiered formularies.
Seven of these looked at the effect of changes in tiered
formularies for non­elderly enrollees of employment­
related private insurance in the United States.
14­20 The
eighth study assessed the impact of changes in tiered
formularies on child dependents of enrollees of
employment­related private insurance plans in the
United States.
21
Impacts of reference pricing policies. The
associations reported in the 3 studies of reference
pricing included in this review are summarized in Table
1. These studies assessed the impact of reference pricing
for a total of 3 categories of drug treatment: nitrate
drugs, angiotensin­converting enzyme (ACE) inhibitors,
and calcium channel blockers (CCBs). Schneeweiss and
colleagues
11­13 and Grootendorst and colleagues
10 found
that between 9% and 34% of patients switched to fully
covered (reference) products after reference pricing was
implemented. Grootendorst and colleagues
10 found that
overall use of CCBs declined upon implementation of
reference pricing, whereas Schneeweiss and colleagues
13
found that the reduction in overall use of CCBs was not
statistically significant after adjustment for pre­policy
trends. The reverse was true for these authors’ findings
with respect to the use of ACE inhibitors.
10,12
Schneeweiss and colleagues
12,13 found that the
changes in utilization associated with reference pricing
resulted in savings to insurers that ranged from 12% to
19% ($1.67 million to $6.7 million per year) of spending
on related medicines. Both sets of researchers found
that reference pricing in British Columbia was
associated with an increase in physician services during
the first 2 to 4 months after the policy change, which
partially offset the savings in drug costs to the
insurer.
10­13 The researchers observed different patterns
with respect to longer­term use of physician services:
Schneeweiss and colleagues
11­13 found no such
association, whereas Grootendorst and colleagues
10
found evidence of increased use of physician services
beyond 4 months for 2 of the 3 categories studied (CCBs
and ACE inhibitors). Schneeweiss and colleagues
12,13
estimated that the annual net savings after accounting
for expenses related to medical care were between $1.62
million and $6 million.
For 2 of the 3 drug categories investigated (CCBs
and ACE inhibitors), Schneeweiss and colleagues
11,13
and Grootendorst and colleagues
10 found that reference
pricing was not associated with any change in the use of
hospital services. In the single study investigating the
impact of reference pricing for nitrate drugs,
Grootendorst and colleagues found that reference
pricing was associated with increased long­term
probability of bypass or revascularization.
10
Impacts of tiered formularies. The associations
observed in the studies of tiered formularies included in
this review are summarized in Table 2. Despite
differences in the populations and drug categories
examined, these studies yielded a number of consistent
findings. Most studies assessing such associations
found that adding tiers to copayments for prescription
drugs in the US private insurance market was
associated with a reduction in total spending (decreases
of 5%–20%).
16,18,20,21 Nair and colleagues
15 did not find
statistically significant associations between adding
tiers to formularies and changes in total spending.
Where such associations were observed, reductions in
total spending were the result of 3 common findings
across the studies and across the drug classes
investigated. Adding tiers to copayment structures was
associated with increased switching within drug classes
in all 8 included studies (switching toward “preferred”
drugs on formulary occurring among 5% to 49.4% of
patients),
14­21 decreased overall utilization of affected
medicines,
15,16,18,19,21 and either no change
21 or an
increase in the rate of discontinuation of prescribed
drug treatments.
14­17,19
In most of the studies that investigated the
distribution of costs, employing tiered formularies was
associated with lower spending by the drug plan
14­
16,20,21 and greater spending by patients.
14­16,19­21 In the
study by Nair and colleagues,
17 changes in spending by
the plan and by patients were consistent with the
findings of other studies but were not statistically
significant.Research Morgan et al
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None of the studies of tiered formularies included in
our review assessed the potential health outcomes
resulting from the policy. However, 2 studies showed
that moving from a 2­tier formulary to a 3­tier
formulary was not associated with increased use of
medical or hospital services.
14,15
The single study of the effects of tiered formularies
on the use of medicines by children was the only study
not to find an association between the policy and
medicine discontinuation.
21 In the single study that
assessed differences in effects on treatments for acute
and chronic conditions, there were greater relative
reductions in the utilization of and persistence with
treatments for acute conditions.
19
Discussion
The rapid rise in the use of tiered formularies by private
insurance plans in the United States may be a harbinger
of future trends in Canada: given rising medicine costs,
it is likely that incentive structures for cost­sharing with
patients will be adopted more widely here in the future.
Policy­makers and health care managers will therefore
require as much evidence as possible regarding such
incentives. In this study, we have weighed the evidence
regarding 2 comparable policy options: tiered
formularies and reference pricing.
Despite over a decade of experience with the
implementation of these policy interventions, and
despite extensive searching of the literature on our part,
we found few studies of the impacts of reference pricing
and tiered formularies that met our relatively strict
inclusion criteria. The most common finding was that
patients facing either reference pricing or tiered
formularies often switched to medications with
preferred coverage. Studies of reference pricing suggest
that this approach is also associated with short­term
increases in the use of physician services, which may be
interpreted as a transaction cost associated with
switching medications. The balance of the evidence
concerning health services use, hospital admissions and
deaths indicates that reference pricing has not been
associated with adverse health impacts. Surprisingly,
only 2 of the 8 studies of tiered formularies included in
this review assessed such outcomes or surrogates
thereof.
14,15 This gap in knowledge is potentially critical,
given that tiered formularies were associated with
reduced use of medicines, increased medicine
discontinuation or both in 7 of the 8 studies of this
policy approach.
14­19,21 More research is required to
examine the hypothesis that tiered formulary policies
may result in increased use of physician services and
potentially worse health outcomes.
The evidence that we examined in this systematic
review suggests that the patient incentives created by
reference pricing policies and tiered formularies work,
insofar as they alter prescription drug use and save on
drug costs. However, the gaps in evidence are sources of
some concern. We conclude that reference pricing has a
slight evidentiary advantage, given that patients’ health
outcomes under tiered formularies have not been
adequately studied and given that tiered formularies
were associated with increased rates of medicine
discontinuation.
Because of our stringent inclusion criteria regarding
study design and outcomes, the final number of studies
included in this systematic review was small. Moreover,
the literature we found pertaining to reference pricing
and tiered copayments described 2 distinct contexts:
public insurance in a Canadian province and private
insurance in the United States. Our focus on studies
published in English is a potential limitation in this
regard, given that there may be non­English literature
concerning reference pricing and tiered formularies in
other settings, such as Germany. The English literature
on experiences outside of North America did not meet
our inclusion criteria.
When policy options for Canada are considered,
information costs and transaction costs for both
prescribers and patients should be taken into account
along with the evidence presented here. With dozens of
potential formularies to consider for their patient
rosters, US physicians may not have the time or
resources necessary to determine for each patient which
drugs are on which tier. Drugs with high copayments
may be prescribed unintentionally under such
circumstances, potentially increasing patients’ costs,
straining physician–patient relationships, reducing
adherence to treatments and worsening health
outcomes. These problems may explain the association
between tiered copayments and medicine
discontinuation in the United States. Such adverse
policy outcomes might be minimized if cost­sharing
with patients, through reference pricing or tiered
formularies, were to be harmonized across all payers
within a jurisdiction (e.g., within each province).
Synthesizing the evidence for the purposes of this
systematic review revealed an important gap in the
existing research: specifically, the impacts of tiered
formulary policies on patients’ health have not been
adequately studied. This gap is particularly significant
given that tiered formularies are associated with
increased rates of medicine discontinuation. Further
research regarding the impact of tiered formularies on
patients’ health outcomes is warranted.
Acknowledgments: We are grateful to Elizabeth Kinney and
Jonathan Lam for assistance with this review.Research Morgan et al
Open Medicine 2009 3(3):1 31 -1 39
Contributors: Steve Morgan was responsible for project
conception and acquisition of funding, reviewing article
titles, abstracts and full text for possible inclusion in the
study, abstracting information from included articles, and
producing the first draft of the research article. Gillian
Hanley was responsible for reviewing full text of articles for
possible inclusion in the study, abstracting information from
included articles, and revising the manuscript for important
intellectual content. Devon Greyson was responsible for
designing and implementing the search strategy, reviewing
article titles, abstracts and full text for possible inclusion in
the study, and revising the manuscript for important
intellectual content. All of the authors gave final approval of
the version to be published.
References
1. Canadian Institute for Health Information. Drug expenditure in
Canada 1985–2007. Ottawa: Canadian Institute for Health
Information: 2008.
2. Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C,
Sturm H. Pharmaceutical policies: effects of reference pricing,
other pricing, and purchasing policies. Cochrane Database Syst
Rev. 2006;(2):CD005979.
3. Puig­Junoy J. What is required to evaluate the impact of
pharmaceutical reference pricing? Appl Health Econ Health
Policy. 2005;4(2):87–98.
4. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing:
associations with medication and medical utilization and
spending and health. JAMA. 2007;298(1):61–69.
5. Dewa CS, Hoch JS. Fixed and flexible formularies as cost­control
mechanisms. Expert Rev Pharmacoecon Outcomes Res.
2003;3(3):303–315.
6. Schneeweiss S. Reference drug programs: effectiveness and
policy implications. Health Policy. 2006;81(1):17–28.
7. Kanavos P, Reinhardt U. Reference pricing for drugs: is it
compatible with U.S. health care? Health Aff (Millwood).
2003;22(3):16–30.
8. Claxton G, Gabel J, DiJulio B, Whitmore H, Pickreign J, Finder
B, et al. Employer health benefits — 2007 annual survey.
Chicago: Kaiser Family Foundation: 2007.
9. Cochrane EPaOofCRG. Data collection checklist. Ottawa:
Cochrane Effective Practice and Organisation of Care Review
Group: 2002.
10. Grootendorst PV, Dolovich LR, Holbrook AM, Levy AR, O­Brien
BJ. The impact of reference pricing of cardiovascular drugs on
health care costs and health outcomes: evidence from British
Columbia. Volume 2: Technical report. Hamilton: MacMaster
University: 2002.
11. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C,
Soumerai SB. Outcomes of reference pricing for angiotensin­
converting­enzyme inhibitors. N Engl J Med.
2002;346(11):822–829.
12. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C,
Walker AM. Impact of reference­based pricing for angiotensin­
converting enzyme inhibitors on drug utilization. CMAJ.
2002;166(6):737–745.
13. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker
AM, Glynn RJ. Clinical and economic consequences of reference
pricing for dihydropyridine calcium channel blockers. Clin
Pharmacol Ther. 2003;74(4):388–400.
14. Motheral B, Fairman KA. Effect of a three­tier prescription copay
on pharmaceutical and other medical utilization. Med Care.
2001;39(12):1293–1304.
15. Fairman KA, Motheral BR, Henderson RR. Retrospective, long­
term follow­up study of the effect of a three­tier prescription
drug copayment system on pharmaceutical and other medical
utilization and costs. Clin Ther. 2003;25(12):3147–3161.
16. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan
KA, Frank RG. The effect of incentive­based formularies on
prescription­drug utilization and spending. N Engl J Med.
2003;349(23):2224–2232.
17. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis
SJ. Effects of a 3­tier pharmacy benefit design on the
prescription purchasing behavior of individuals with chronic
disease. J Manag Care Pharm. 2003;9(2):123–133.
18. Gibson TB, McLaughlin CG, Smith DG. A copayment increase for
prescription drugs: the long­term and short­term effects on use
and expenditures. Inquiry. 2005;42(3):293–310.
19. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of
3­tier pharmacy benefit design and increased consumer cost­
sharing on drug utilization. Am J Manag Care.
2005;11(10):621–628.
20. Landon BE, Rosenthal MB, Normand ST, Spettell C, Lessler A,
Underwood HR, et al. Incentive formularies and changes in
prescription drug spending. Am J Manag Care. 2007;13(6 Pt
2):360–369.
21. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan
KA, Muriel AC, et al. Impact of 3­tier formularies on drug
treatment of attention­deficit/hyperactivity disorder in children.
Arch Gen Psychiatry. 2005;62(4):435–441.
Citation: Morgan S, Hanley G, Greyson D. Comparison of
tiered formularies and reference pricing policies: a
systematic review Open Med 2009;3(3):131‐139
Published: 4 August 2009
Copyright: Open Medicine applies the Creative Commons
Attribution Share Alike License, which means that anyone is
able to freely copy, download, reprint, reuse, distribute,
display or perform this work and that authors retain
copyright of their work. Any derivative use of this work must
be distributed only under a license identical to this one and
must be attributed to the authors. Any of these conditions
can be waived with permission from the copyright holder.
These conditions do not negate or supersede Fair Use laws in
any country.